Riskpilot← Back to searchSign inGet full accessMEDI-TRADE ApS
APSActiveCVR 20484675Grusbakken 2DWholesale of pharmaceutical and medical goods · NACE 4646Est. 19971 employees
Revenue 2025
DKK -39K
-50% vs 2024
EBITDA margin
100.0%
+76% vs 2024
Equity ratio
99.6%
Financial strength
Net profit 2025
DKK 1,9M
-40% vs 2024
| Revenue | DKK -39K | -50% |
| EBITDA | DKK -39K | +76% |
| Net profit | DKK 1,9M | -40% |
| Total assets | DKK 20,8M | +4% |
| Equity | DKK 20,7M | +4% |
| Employees | 1 | — |
Legal name
MEDI-TRADE ApS
CVR number
20484675
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. december 1997
Share capital
DKK 125.000
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 medlemmer af bestyrelsen i forening, af direktøren sammen med et andet bestyrelsesmedlem i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive handel og fabrikation og at investere i andre selskaber med dette formål.
Address
Grusbakken 2D
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -15 | — | 0 | — | -88 | -14 | -9 | -361 | -135 | -135 | -9 | -37 | -77 | -39 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -82 | -0 |
| EBITDA | -15 | -47 | -25 | -46 | -88 | -14 | -9 | -361 | -135 | -135 | -9 | -37 | -159 | -39 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -15 | -47 | -25 | -46 | -88 | -14 | -9 | -361 | -135 | -135 | -9 | -37 | -159 | -39 |
| Net financials | 83 | 4 | 68 | 1.333 | 607 | 1.287 | 1.841 | 1.620 | 3.230 | 4.455 | 2.432 | 2.628 | 3.267 | 1.898 |
| Profit before tax | 68 | -44 | 43 | 1.287 | 519 | 1.273 | 1.832 | 1.259 | 3.095 | 4.320 | 2.423 | 2.592 | 3.108 | 1.859 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 68 | -44 | 43 | 1.287 | 519 | 1.273 | 1.832 | 1.259 | 3.095 | 4.320 | 2.423 | 2.592 | 3.108 | 1.859 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 36 | 8 | 14 | 771 | 1.030 | 2.271 | 3.973 | 5.193 | 8.171 | 12.373 | 14.679 | 17.157 | 19.933 | 20.823 |
| Equity | -721 | -765 | -722 | 565 | 953 | 2.226 | 3.927 | 5.186 | 8.163 | 12.366 | 14.671 | 17.145 | 19.884 | 20.743 |
| Long-term debt | 0 | 758 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 758 | 15 | 736 | 206 | 77 | 45 | 46 | 8 | 8 | 8 | 8 | 12 | 49 | 80 |
| Total debt | 758 | 773 | 736 | 206 | 77 | 45 | 46 | 8 | 8 | 8 | 8 | 12 | 49 | 80 |
EBITDA margin
-3866300.0%
This company
15.8%
Market median
-24470353% vs market
20122025
Equity ratio
99.6%
This company
38.2%
Market median
+161% vs market
20122025
Return on equity
9.0%
This company
18.4%
Market median
-51% vs market
20122025
Net profit margin
185905900.0%
This company
8.1%
Market median
+2295134468% vs market
20122025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PS | Audit | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1997 | — | — | |
| Board of Directors | 1997 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2014 | |
| Individual | 25.0% | 25.0% | 2014 | |
| Individual | 25.0% | 25.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MEDI-TRADE ApS 
ELDON BIOLOGICALS A/SBoard members of MEDI-TRADE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Sleimann Petersen | Audit | 0 companies |
| Hans-Ole Hedegaard | Board of Directors | 0 companies |
| Ellen Juul Hedegaard | Board of Directors | 0 companies |